Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

53.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.5K
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.5K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.5K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.8K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.8K
Cancer Prevention02:59

Cancer Prevention

7.6K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.6K
What is Cancer?02:12

What is Cancer?

14.0K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.0K
Cancer Survival Analysis01:21

Cancer Survival Analysis

645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Documentation of biological treatment in asthma].

Pneumologie (Stuttgart, Germany)·2026
Same author

Is the SUNRISE study a new dawn in steroid stewardship?

The Lancet. Respiratory medicine·2026
Same author

[Clinical and economic role of FeNO measurements in adults with asthma].

Pneumologie (Stuttgart, Germany)·2026
Same author

Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.

The journal of allergy and clinical immunology. In practice·2026
Same author

Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments.

Allergy·2026
Same author

Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

Related Experiment Videos

[Lung cancer].

Berthold Fischer1, Roland Buhl

  • 1III. Medizinische Klinik und Poliklinik, Schwerpunkt Pneumologie, Klinikum der Johannes Gutenberg-Universität, Langenbeckstrasse 1, 55131 Mainz. b.fischer@3-med.klinik.uni-mainz.de

Medizinische Klinik (Munich, Germany : 1983)
|May 20, 2008
PubMed
Summary
This summary is machine-generated.

Lung cancer incidence is declining in men but rising in women in Germany. Research is exploring targeted therapies like EGFR inhibitors and bevacizumab for advanced non-small cell lung cancer (NSCLC) to improve patient outcomes.

Related Experiment Videos

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Lung cancer incidence shows a declining trend in German men since the late 1980s, contrasting with a persistent rise in women.
  • Currently, no approved lung cancer screening program exists, with ongoing anticipation for results from major randomized trials.
  • Adjuvant chemotherapy has proven beneficial in improving cure rates for stage II and IIIA non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To review current trends and therapeutic strategies in lung cancer, particularly non-small cell lung cancer (NSCLC).
  • To discuss the role of targeted therapies, including epidermal growth factor receptor (EGFR) inhibitors and bevacizumab, in advanced NSCLC treatment.
  • To highlight the importance of patient selection for bevacizumab therapy and ongoing research into novel multitargeted agents.

Main Methods:

  • Review of existing clinical trial data and approved therapeutic modalities for NSCLC.
  • Analysis of epidemiological trends in lung cancer incidence in Germany.
  • Discussion of molecular targets such as EGFR and vascular endothelial growth factor (VEGF) in NSCLC.

Main Results:

  • Epidermal growth factor receptor (EGFR) is frequently overexpressed in NSCLC, leading to the approval of erlotinib for advanced stages.
  • Bevacizumab, an anti-VEGF antibody, combined with chemotherapy, shows improved outcomes in advanced NSCLC, with specific patient selection crucial for safety.
  • Ongoing clinical trials are investigating multitargeted agents like sorafenib, sunitinib, and vandetanib.

Conclusions:

  • Adjuvant chemotherapy is established for improving cure rates in early-stage NSCLC.
  • Targeted therapies, including EGFR inhibitors and bevacizumab, offer new avenues for advanced NSCLC treatment, necessitating careful patient selection.
  • Future research focuses on multitargeted agents to further enhance therapeutic efficacy in lung cancer.